Bioxcel therapeutics, inc. (BTAI)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Revenues

-

-

-

-

-

-

-

-

-

-

0

0

0

Operating costs and expenses
Research and development

32,494

25,797

25,320

22,019

17,294

14,558

9,966

6,764

5,307

2,690

0

0

0

General and administrative

8,684

7,804

7,181

6,467

5,801

5,404

5,209

4,209

2,987

1,847

0

0

0

Total operating expenses

41,178

33,601

32,501

28,486

23,095

19,962

0

0

0

-

0

0

-

Total operating expenses

-

-

-

-

-

-

-

-

-

-

-

-

0

Loss from operations

-41,178

-33,601

-32,501

-28,486

-23,095

-19,962

-15,175

-10,973

-8,294

-4,537

0

0

0

Other income
Dividend and interest income, net

503

633

733

849

903

692

0

0

0

-

-

-

-

Net loss

-40,675

-32,968

-31,768

-27,637

-22,192

-19,270

-14,723

-10,753

-8,292

-4,539

0

0

0

Net loss per share attributable to common stockholders basic and diluted

-0.79

-0.45

-0.57

-0.54

-0.46

-0.45

-0.31

-0.19

-0.37

-0.25

-0.10

-0.06

-0.06

Weighted average shares outstanding - basic and diluted

18,968

18,072

15,752

15,668

15,663

15,538

15,645

15,645

11,456

10,296

9,483

9,480

9,480